Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Americans are getting slimmer. The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that: ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Zepbound is the newest addition to the weight loss drug arena. In November 2023, it joined the list of obesity-fighting drugs – administered as an injection – to be approved by the U.S. Food and Drug ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

It's been an excellent year for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech company. Viking Therapeutics' leading candidate, VK2735, is a potential GLP-1 weight loss medicine. It reported ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

U.S. Surgeon General Vivek Murthy said Friday that two alcoholic drinks a day increases the risk for seven types of cancer, calling for cancer warning labels on alcohol.

"This is because weight loss primarily leads to the loss of body fat, but also commonly leads to the loss of some muscle." Lilly's Zepbound has become the first drug approved by the FDA for obese ...

Vincent (oblique) has been downgraded to doubtful for Thursday's game against the Blazers, Dan Woike of the Los Angeles Times reports. Vincent missed Tuesday's game against the Cavaliers and ...